Oncotelic Therapeutics, Inc. financial data

Symbol
OTLC on OTC
Industry
Pharmaceutical Preparations
Location
29397 Agoura Rd., #107, Aguora Hills, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
MATEON THERAPEUTICS INC (to 3/26/2021), OXIGENE INC (to 6/3/2016)
Latest financial report
10-K - Q4 2024 - Apr 15, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.17 % -30.1%
Debt-to-equity 183 %
Return On Equity -47.2 % +19.3%
Return On Assets -16 % +36.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 408M shares +2.15%
Common Stock, Shares, Outstanding 407M shares +2.03%
Common Stock, Value, Issued 4.07M USD +2.03%
Weighted Average Number of Shares Outstanding, Basic 404M shares +5.29%
Weighted Average Number of Shares Outstanding, Diluted 407M shares +2.39%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 70K USD
Research and Development Expense 21.2K USD
General and Administrative Expense 376K USD -34.5%
Operating Income (Loss) -3.58M USD +46.2%
Nonoperating Income (Expense) -1.2M USD +22.8%
Net Income (Loss) Attributable to Parent -4.52M USD +42.8%
Earnings Per Share, Basic -0.01 USD/shares +50%
Earnings Per Share, Diluted -0.01 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 149K USD
Accounts Receivable, after Allowance for Credit Loss, Current 19K USD 0%
Assets, Current 134K USD -50.6%
Goodwill 2.79M USD -53.4%
Assets 26.7M USD -11.1%
Accounts Payable, Current 343K USD -82.4%
Liabilities, Current 19.2M USD +16.3%
Liabilities 19.2M USD +4.33%
Retained Earnings (Accumulated Deficit) -38M USD -13.5%
Stockholders' Equity Attributable to Parent 8.25M USD -32%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 7.48M USD -35.6%
Liabilities and Equity 26.7M USD -11.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -231K USD +7.81%
Net Cash Provided by (Used in) Financing Activities 250K USD +25%
Common Stock, Shares Authorized 750M shares 0%
Common Stock, Shares, Issued 407M shares +2.03%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 18.6K USD
Interest Paid, Excluding Capitalized Interest, Operating Activities 94.8K USD -5.05%
Deferred Tax Assets, Valuation Allowance 12.8M USD -4.71%
Deferred Tax Assets, Gross 12.8M USD -4.71%
Deferred Tax Assets, Operating Loss Carryforwards 10M USD -4.43%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 15M shares 0%
Additional Paid in Capital 42.2M USD +1.36%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 0 USD
Interest Expense 885K USD -71.1%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%